Ganciclovir Sodium

Category	Cytomegalovirus (CMV)
CAS	107910-75-8
Description	Ganciclovir Sodium is a potent inhibitor of the Herpesvirus family including cytomegalovirus. It is an acyclovir analog. It is used to treat complications from AIDS-associated cytomegalovirus infections. It was developed by Roche and has been listed.

Quotation Now

Product Information

Synonyms	2-Amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6h-purin-6-one sodium salt;9-[[1-(Hydroxymethyl)-2-hydroxyethoxy]methyl]-2-amino-9H-purine-6(1H)-one/sodium,(1:1) salt;Ganciclovir monosodium salt;6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, monosodium salt;RS-21592 sodium;RS21592 Sodium;Sodium 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate
Molecular Weight	277.21
Molecular Formula	C9H12N5NaO4
Canonical SMILES	C1=NC2=C(N1COC(CO)CO)N=C(N=C2[O-])N.[Na+]
InChI	InChI=1S/C9H13N5O4.Na/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);/q;+1/p-1
InChIKey	JJICLMJFIKGAAU-UHFFFAOYSA-M
Boiling Point	675°Cat760mmHg
Melting Point	250°C(decomposition)
Flash Point	209.9°C
Purity	98%
Density	1.81g/cm3
Solubility	10 mM in DMSO
Appearance	Solid powder
Application	Ganciclovir Sodium is used to treat complications from AIDS-associated cytomegalovirus infections.
Shelf Life	2 month in rt, long time
Storage	-20°C Freezer
Complexity	273
Exact Mass	277.07869816
Index Of Refraction	1.493
In Vitro	Ganciclovir sodium is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The primary mechanism of ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir sodium is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase.
In Vivo	Ganciclovir sodium (1-80 mg/kg; i.h.; daily for 5 days) delays MCMV-induced wasting syndrome and mortality. Result: Dose dependently delayed MCMV-induced wasting syndrome and mortality.
PSA	38.77000
Target	CMV; HSV; Antibiotic; Nucleoside Antimetabolite/Analog
Vapor Pressure	2.23E-07mmHg at 25°C